We are live on ! Find out more
ARDS

Aridis Pharmaceuticals Inc. Common Stock
ARDS

Delisted

ARDS was delisted on the 18th of July, 2023.

Back to rankings

6 hedge funds and large institutions have $477K invested in Aridis Pharmaceuticals Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

20% more funds holding

Funds holding: 5 → 6 (+1)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

26% less capital invested

Capital invested by funds: $642K → $477K (-$165K)

Holders
6
Holders Change
+1
Holders Change %
+20%
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$11.8K
2
UBS Group
UBS Group
Switzerland
+$3.96K
3
Bank of America
Bank of America
North Carolina
+$1.1K
4
TRCT
Tower Research Capital (TRC)
New York
+$366

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$118K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$22.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$440K -$22.9K -2,384 -5%
UBS Group
2
UBS Group
Switzerland
$21K +$3.96K +412 +25%
BlackRock
3
BlackRock
New York
$12K +$11.8K +1,222 New
Wells Fargo
4
Wells Fargo
California
$3K – – –
Bank of America
5
Bank of America
North Carolina
$1K +$1.1K +114 New
Millennium Management
6
Millennium Management
New York
– -$118K -10,763 Closed
TRCT
7
Tower Research Capital (TRC)
New York
– +$366 +38 New

ARDS Hedge Fund Activity: Q2 2019 in Review

6 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Aridis Pharmaceuticals Inc. Common Stock (ARDS) for Q2 2019, worth a combined $477K — down 26% from $642K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new ARDS positions and 2 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.

The largest buyer was BlackRock, opening a new position worth an estimated $11.8K. The largest seller was Millennium Management, exiting entirely with an estimated $118K sold.

  • 6 institutional investors held Aridis Pharmaceuticals Inc. Common Stock (ARDS) as of Q2 2019, up from 5 in Q1 2019.
  • Funds reported $477K of Aridis Pharmaceuticals Inc. Common Stock stock for Q2 2019, down 26% quarter-over-quarter.
  • 3 funds opened new Aridis Pharmaceuticals Inc. Common Stock positions in Q2 2019 and 2 closed out, a net change of +1 holder.
  • The largest Aridis Pharmaceuticals Inc. Common Stock buyer in Q2 2019 was BlackRock, an estimated $11.8K added.
  • The largest Aridis Pharmaceuticals Inc. Common Stock seller in Q2 2019 was Millennium Management, an estimated $118K sold.

Based on aggregated 13F filings for Q2 2019.